Annovis Bio reports Q4 2022 net loss of $7.7M; advances buntanetap trials

Annovis Bio, Inc.

2023-Q1 EPS reported -$1.19

Net loss Q4 2022 of $7.7M vs $5.9M in Q4 2021; full-year net loss $25.3M vs $14.5M.
Cash and equivalents $28.4M as of Dec 31, 2022; R&D spend $6.2M in Q4, up 114% YoY.
FDA authorized Phase 2/3 Alzheimer's trial; EU sites approved for Phase 3 Parkinson's trial.
Interim analysis for Phase 3 PD trial based on 132 patients; company proceeds as planned.
Appointed VP Process Chemistry and VP Toxicology; filed patent for neuropsychiatric uses.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Annovis Bio, Inc. reported the quarter and year ended December 31, 2022 results: net income net loss of $7.7 million, compared to a net loss of $5.9 million for the same period in 2021.

Period: the quarter and year ended December 31, 2022
Net income: net loss of $7.7 million, compared to a net loss of $5.9 million for the same period in 2021
Result: reported results

Exact text from the filing

On April 3, 2023, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2022 and providing a corporate update.

View on SEC.gov

Browse all earnings releases →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-040537

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.